leadf
logo-loader
RNS
viewDechra Pharmaceutical

Dechra Pharm PLC - Director/PDMR Shareholding

RNS Number : 6654C
Dechra Pharmaceuticals PLC
20 October 2020
 



 

 

 

20 October 2020

 

Dechra® Pharmaceuticals PLC

(Dechra or the Company)

LEI: 213800J4UVB5OWG8VX82

 

Notification and public disclosure of transactions by

persons discharging managerial responsibilities (PDMRs)

 

 

 

Grant of SAYE options:

 

Dechra Pharmaceuticals PLC announces that on 19 October 2020 the following PDMRs were granted options over ordinary shares of 1p each in the Company pursuant to the Dechra Global Save As You Earn Plan 2018 (the Options).

 

The Options have been granted with an exercise price of £28.68.

 

 

Name

Capacity

Options Granted

Ian Page

Director

627

Paul Sandland

Director

627

 

 

The Notification of Dealing Forms set out below are provided in accordance with the requirements of the EU Market Abuse Regulation.

 

Notification of Dealing Form

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Ian Page

 

2.

Reason for the notification

a)

Position/status

Director/PDMR

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Grant of 627 options under the Company's Save As You Earn Scheme

c)

Price(s) and volumes(s)

Price(s)

£28.68

Volume(s)

627

d)

Aggregated information

-    Aggregate volume

-    Price

 

 

627

£17,982.36

e)

Date of the transaction

2020.10.19

f)

Place of the transaction

Outside a trading venue

 

1.

Details of the Person Discharging Managerial Responsibility ("PDMR")/person closely associated with them ("PCA")

a)

Name

Paul Sandland

 

2.

Reason for the notification

a)

Position/status

Director/PDMR

 

b)

Initial notification/

amendment

Initial Notification

3.

Details of the Issuer

a)

Name

Dechra Pharmaceuticals PLC

b)

LEI code

213800J4UVB5OWG8VX82

 

4.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

a)

Description of the financial instrument

 

Identification code

Ordinary Shares of 1 pence each

 

 

ISIN: GB0009633180

b)

Nature of the transaction

Grant of 627 options under the Company's Save As You Earn Scheme

c)

Price(s) and volumes(s)

Price(s)

£28.68

Volume(s)

627

d)

Aggregated information

-    Aggregate volume

-    Price

 

 

627

£17,982.36

e)

Date of the transaction

2020.10.19

f)

Place of the transaction

Outside a trading venue

 

 

For further information, please contact:

 

Melanie Hall, Company Secretary                          

Telephone number: 01606 814730

 

 

 

About Dechra

Dechra is a global specialist veterinary pharmaceuticals and related products business.  Our expertise is in the development, manufacture, marketing and sales of high quality products exclusively for veterinarians worldwide. Dechra's business is unique as the majority of its products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products.  For more information please visit: www.dechra.com

 

Trademarks

Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHKKKBPKBDDCKB

Quick facts: Dechra Pharmaceutical

Price: -

Market: LSE
Market Cap: -
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

5 min read